Table 1. Patient characteristics.

Age in years, at study enrollment, median (min, max)	9 (3–17)
Number of courses of vemurafenib: median (min, max)	23 (4–64)
Number of Prior Therapies	Number of patients
One	4
Two	4
Three or more	11
	Number	Percentage
Gender
Males	9	47.4
Females	10	52.6
Race
White, non-Hispanic	14	73.7
Black	2	10.5
Unknown	3	15.8
Diagnosis
Astrocytoma (NOS)	1	5.3
Fibrillary Astrocytoma	1	5.3
Pilocytic Astrocytoma	10	52.6
Ganglioglioma	5	26.3
Pleomorphic Xanthoastrocytoma	2	10.5